Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

NCT06116461 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT06116461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
Lead sponsor
Erasmus Medical Center
Phase
Phase 4
Overall status
Unknown status
Start date
January 5, 2022
Completion date
January 31, 2025
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma